Drug-eluting balloon as an alternative to coronary stent in the treatment of de novo atherosclerotic lesions of native coronary arteries — the future we have already been in? Review

In the last decade, the disadvantages of coronary artery (CA) drugeluting stenting have become increasingly obvious. Metallization of the artery, loss of vasoreactivity and chronic inflammation at the implantation site lead to restenosis and an increased risk of repeated revascularization. In this regard, the "leaving nothing behind" concept is attracting increasing interest, which came to coronary revascularization from lower limb arterial disease strategies. The treatment methods within this concept in CA include the use of biodegradable scaffolds and drug-eluting balloons (DEB). Despite the fact that both Russian and foreign guidelines for DEB establish the role of in-stent restenosis treatment, large studies demonstrate the efficacy and safety of DEB in the treatment of de novo coronary lesions. The review systematizes the latest data on the DEB potential in the treatment of de novo native coronary lesions.